US 12,139,530 B2
Bispecific antibody specifically binding to IL-17A and TNF-α
Jae Bong Yoon, Daejeon (KR); Eun Young Jeon, Daejeon (KR); Gi Sun Baek, Daejeon (KR); Seok Ho Yoo, Daejeon (KR); Bum-Chan Park, Daejeon (KR); and Young Woo Park, Daejeon (KR)
Assigned to Y-BIOLOGICS INC., Daejeon (KR)
Appl. No. 17/430,144
Filed by Y-BIOLOGICS INC., Daejeon (KR)
PCT Filed Apr. 20, 2020, PCT No. PCT/KR2020/005213
§ 371(c)(1), (2) Date Aug. 11, 2021,
PCT Pub. No. WO2020/218791, PCT Pub. Date Oct. 29, 2020.
Claims priority of application No. 10-2019-0049177 (KR), filed on Apr. 26, 2019.
Prior Publication US 2022/0098297 A1, Mar. 31, 2022
Int. Cl. C07K 16/24 (2006.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); A61P 37/06 (2006.01); C12N 5/00 (2006.01); C12N 15/85 (2006.01)
CPC C07K 16/244 (2013.01) [A61K 47/6845 (2017.08); A61P 37/06 (2018.01); C07K 16/241 (2013.01); C12N 5/0018 (2013.01); C12N 15/85 (2013.01); A61K 2039/5156 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C12N 2800/107 (2013.01)] 21 Claims
 
1. A bispecific antibody specifically binding to IL-17A (interleukin-17A) and TNF-α (tumor necrosis factor-alpha) comprising an antibody specifically binding to IL-17A or an antigen binding fragment thereof and an antibody specifically binding to TNF-α or an antigen binding fragment thereof characterized in that the antibody specifically binding to IL-17A or an antigen binding fragment thereof contains
(i) heavy chain CDR1 of SEQ ID NO: 1, heavy chain CDR2 of SEQ ID NO: 2, and heavy chain CDR3 of SEQ ID NO: 3;
heavy chain CDR1 of SEQ ID NO: 1, heavy chain CDR2 of SEQ ID NO: 4, and heavy chain CDR3 of SEQ ID NO: 5;
heavy chain CDR1 of SEQ ID NO: 1, heavy chain CDR2 of SEQ ID NO: 4, and heavy chain CDR3 of SEQ ID NO: 6;
heavy chain CDR1 of SEQ ID NO: 1, heavy chain CDR2 of SEQ ID NO: 4, and heavy chain CDR3 of SEQ ID NO: 7;
heavy chain CDR1 of SEQ ID NO: 8, heavy chain CDR2 of SEQ ID NO: 9, and heavy chain CDR3 of SEQ ID NO: 10; or
heavy chain CDR1 of SEQ ID NO: 8, heavy chain CDR2 of SEQ ID NO: 11, and heavy chain CDR3 of SEQ ID NO: 10, and
(ii) light chain CDR1 of SEQ ID NO: 12; light chain CDR2 of SEQ ID NO: 13; and light chain CDR3 of SEQ ID NO: 14.